- Report
- February 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- January 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Clinical Trials
- April 2024
- 65 Pages
Global
From €1442EUR$1,500USD£1,237GBP
- Report
- July 2018
- 115 Pages
Global
From €1322EUR$1,375USD£1,134GBP
€2644EUR$2,750USD£2,268GBP
- Report
- January 2022
- 120 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2022
- 60 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- January 2022
- 200 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Report
- January 2023
- 175 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- August 2022
- 120 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- October 2021
- 112 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Clinical Trials
- March 2020
- 386 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- May 2023
- 121 Pages
Global
From €3500EUR$3,899USD£3,108GBP
Chemotherapy Induced Nausea (CIN) drugs are a type of oncology drug used to treat the nausea and vomiting caused by chemotherapy. CIN drugs are typically administered before, during, or after chemotherapy to reduce the severity of nausea and vomiting. Common CIN drugs include 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These drugs work by blocking the action of serotonin and other chemicals in the brain that cause nausea and vomiting.
CIN drugs are an important part of cancer treatment, as they can help reduce the side effects of chemotherapy and improve the quality of life for cancer patients. CIN drugs are available in both oral and intravenous forms, and are often used in combination with other anti-nausea medications.
Companies in the CIN drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
